Biogen (BIIB) Tops Q2 EPS by 59c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'
July 26, 2017 10:53 AM EDTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $328.00 (from $317.00) while maintaining a Market Perform rating, following the company's second quarter earnings announcement.
Analyst M. Ian Somaiya notes the company delivered second quarter earnings per share and revenues above consensus... More
Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q
July 26, 2017 8:44 AM EDTUBS raised its price target on Biogen (NASDAQ: BIIB) to $285.00 (from $270.00) while maintaining a Neutral rating following the company's 2Q. BIIB recorded a $284M top-line beat. EPS also came in ahead with a $0.53 beat.
Despite a strong 2Q print, the mid-to-long term outlook... More
Biogen (BIIB) PT Raised to $319 at Deutsche Bank
July 26, 2017 6:24 AM EDTDeutsche Bank raised its price target on Biogen (NASDAQ: BIIB) to $319.00 (from $315.00) while maintaining a Buy rating amid solid Q2 results and strategic review.
Analyst Andrew Peters commented, "The outperformance, driven primarily by strength in the MS franchise, as well as by continued... More
